Avacta, Daewoong partner on COVID-19 therapy

By The Science Advisory Board staff writers

Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong, will develop a novel class of mesenchymal stem cell treatments that are engineered to also produce Affimer therapies in patients at a selected site of action.

Now, the collaboration will also include the development of therapies that repair lung damage caused by COVID-19 while also producing neutralizing Affimer molecules that prevent disease progression.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: